In January 2003, DePuy, Inc., a Johnson & Johnson company, reported its subsidiary DePuy AcroMed, Inc. had signed a definitive agreement to acquire substantially all of the assets of Orquest, Inc. Orquest, Inc. had been working on biological matrices that direct the regeneration of bone, cartilage, and other soft skeletal tissue effcetively using biomaterials promote the body's own natural healing process to regenerate skeletal tissue. Orquest had been a privately held, medical technology company dedicated to setting new standards of care in orthopedics through biological solutions. With two platform technologies and several novel products in the clinic, in the field of orthobiologics, the Company's products had encompassed the major growth markets in orthopedics: spinal surgery, fracture repair, and cartilage regeneration.
